SNYNF - Denali slips as Sanofi fails in mid-stage trial for ALS therapy
2024-02-16 10:05:39 ET
More on Denali, Sanofi, etc.
- Sanofi (SNY) Q4 2023 Earnings Call Transcript
- Sanofi 2023 Q4 - Results - Earnings Call Presentation
- Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition
- Sanofi, Regeneron win Japan approval for Dupixent in CSU indication
- Sanofi incurs loss in Q4 amid generic competition, currency woes